In this issue:
Significant delays in diagnosis and high rates of comorbidities in paediatric patients
Contribution of genetics to the susceptibility to HS
Real-world survival of TNF inhibitors in HS
A simplified patient global assessment item to evaluate health-related quality of life in HS
Adalimumab safe and effective but needs to be utilised earlier in disease course
Could radiotherapy be an option for treatment-resistant HS?
Promising novel therapeutic targets
There is a bidirectional association between HS and atopic dermatitis
Please login below to download this issue (PDF)